However, despite previous reports on the potential advantage posed by GLP1-based multi-agonists in the management of obesity and metabolic disease, as recently exemplified by the dramatic body weight-lowering actions of the GLP1/GIP dual agonist, tirzepatide 47 , to our knowledge, no study has addressed to date the pharmacological characterization of GLP1-based unimolecular multi-agonists for management of reproductive and metabolic alterations of PCOS, using suitable preclinical models, as pre-requisite for their application in clinics
Dipeptidyl peptidase IV (CD26) role in the inactivation of regulatory peptides
10.1016/s0140-6736(13)60439-0 40 EirinA.LermanA.LermanL
Simethicone and bismuth subsalicylate drug information
Li X, Zhang Q, Zhou X, Guo S, Jiang S, Zhang Y, Zhang R, Dong J, Liao L
For more information on our use of your personal information and your rights, see our privacy policy